Trump’s TrumpRx prescription drug platform has announced the addition of hundreds of generic medications, aiming to lower drug prices in the US. The expansion is part of the administration’s effort to reduce healthcare costs.

On May 5, 2026, the US Food and Drug Administration commissioner publicly defended the agency’s drug approval decisions, responding to criticism from the pharmaceutical industry and some members of Congress.

The Controversy

Several pharmaceutical companies have expressed dissatisfaction with the FDA’s approval pace and standards, arguing the agency has been overly cautious on certain medications. Some lawmakers have also raised concerns.

Commissioner Response

The FDA commissioner emphasized that approval standards will not be lowered under political or commercial pressure, and that protecting public health remains the agency’s top priority. The agency will continue to base approval decisions on scientific evidence.

The U.S. Food and Drug Administration has approved expanded access to daraxonrasib, a targeted pancreatic cancer drug developed by Revolution Medicines, according to The New York Times and Reuters. The decision opens the door for more patients awaiting treatment to receive a therapy that has demonstrated significant efficacy in clinical trials.

A Breakthrough Therapy

Daraxonrasib is a targeted inhibitor directed at the KRAS G12D mutation. KRAS mutations are among the most common driver alterations in pancreatic cancer, found in approximately 35% to 40% of pancreatic ductal adenocarcinoma cases. For decades, the KRAS protein was considered “undruggable” due to its structural characteristics, but a new generation of covalent inhibitors has changed that landscape.

Reuters reports that in early-stage clinical trials, daraxonrasib caused significant tumor shrinkage in some patients with advanced pancreatic cancer. Notably, the spouse of former Senator Ben Sasse has shown encouraging results on the drug, drawing widespread public attention.

What Expanded Access Means

The FDA’s expanded access program — also known as “compassionate use” — allows unapproved drugs to be used by patients with serious or life-threatening conditions who cannot enroll in clinical trials. The approval of this pathway means more patients who are ineligible for trial participation can gain early access to treatment.

The Washington Post notes that the speed of the expanded access approval reflects the FDA’s strong confidence in the drug’s efficacy data. While such approvals typically take several weeks, this one was processed in under two weeks.

The Challenge of Pancreatic Cancer

Pancreatic cancer is often called the “king of cancers” and ranks as the fourth leading cause of cancer-related death in the United States. Due to its subtle early symptoms, difficulty in detection, and limited treatment options, the five-year survival rate has long hovered around just 12%.

Revolution Medicines’ Chief Medical Officer stated: “We are pleased to work with the FDA to give more patients in desperate need the opportunity to receive daraxonrasib. This is an important step toward transforming the pancreatic cancer treatment landscape.”

Market Outlook

Industry analysts project that if daraxonrasib continues to demonstrate positive data in later-stage trials, it could receive full FDA approval by 2027. At that point, the KRAS-targeted therapy market is expected to reach tens of billions of dollars, covering indications in pancreatic cancer, colorectal cancer, and non-small cell lung cancer.

Source: The New York Times · Reuters · USA Today

A US federal appeals court issued a temporary order on Thursday blocking the Food and Drug Administration’s (FDA) rule that allowed women to obtain the abortion drug mifepristone by mail, CNN and The New York Times reported. The ruling will have significant implications for medication abortion accessibility across the country.

The Ruling

The appeals court’s temporary order effectively suspends the FDA’s expanded policy that permitted certified healthcare providers to mail mifepristone to patients. Mifepristone is the primary drug used in medication abortions, which currently represent the most common method for the procedure in the United States.

The ruling is the latest development in an ongoing legal campaign by anti-abortion organizations and state governments challenging the FDA’s regulatory decisions on the drug. Opponents argue that mailing prescription abortion drugs poses safety risks and should be subject to stricter oversight.

Impact

The mifepristone-misoprostol medication abortion regimen is currently the most prevalent method for terminating early pregnancies in the US. The FDA’s previous rule allowing mail distribution of the drug significantly expanded access for women in remote areas and states with restrictive abortion laws.

The temporary order will reintroduce barriers to medication access for this population, particularly in states that have implemented strict abortion restrictions.

Reactions

Pro-choice organizations strongly condemned the ruling, arguing it infringes on personal medical autonomy. Related legal groups have indicated they will continue pursuing legal avenues to defend the FDA’s original policy.

Conversely, anti-abortion groups welcomed the ruling as an interim victory and called on the court to permanently overturn the FDA’s mail distribution rule.

Legal Background

The FDA’s regulatory approach to mifepristone has undergone several changes in recent years. In 2021, the agency eliminated the in-person dispensing requirement, allowing the drug to be distributed by mail. Since then, anti-abortion states and organizations have filed multiple lawsuits seeking to reverse this policy change.

It remains unclear whether the appeals court’s temporary order will persist and how the case will proceed through higher levels of the judicial system.

Source: CNN, The New York Times

On April 30, 2026, the BBC reported a breakthrough medical AI application: artificial intelligence systems are helping doctors detect “hidden sperm” in semen samples from men previously diagnosed with azoospermia — a condition characterized by the complete absence of sperm. This technological breakthrough is bringing new hope to millions of men who were previously told they could not father children biologically.

How the Technology Works

Traditional semen analysis relies on laboratory technicians manually examining samples under a microscope to detect the presence of sperm. However, when sperm counts are extremely low, even experienced technicians may miss them. AI systems, using deep learning algorithms, can perform more systematic and precise analyses of semen samples, identifying trace amounts of sperm that the human eye might overlook.

According to the BBC, this AI system has been trained on hundreds of thousands of semen samples and can detect extremely low sperm concentrations with far greater precision than human examination. In some cases, the AI has successfully found viable sperm suitable for in vitro fertilization (IVF) in samples that humans had diagnosed as containing “zero sperm.”

Clinical Significance

For men diagnosed with azoospermia, this discovery carries profound significance. Traditionally, azoospermia meant that sperm could not be obtained through conventional means for assisted reproduction. However, AI technology applications suggest that some men diagnosed with azoospermia actually have trace amounts of sperm that could be used for fertilization through intracytoplasmic sperm injection (ICSI) techniques.

Reproductive medicine experts note that approximately 1% to 2% of men worldwide are affected by azoospermia, and a significant portion of these may have “pseudo-azoospermia” — meaning trace sperm exists but went undetected. The adoption of AI technology could enable these patients to regain fertility.

Real-World Applications

The report noted that several reproductive medicine centers have already begun deploying this AI-assisted detection system. In early applications, the system successfully found usable sperm in approximately 15% to 20% of samples diagnosed as azoospermic — a discovery rate far exceeding that of traditional detection methods.

Ethical Considerations

While the technology brings enormous medical value, it has also sparked ethical discussion. Some experts caution that the accuracy and reliability of AI diagnosis still need to be validated through larger-scale clinical trials. Additionally, how to distribute this new technology equitably in resource-limited settings remains a concern.

The reproductive medicine community broadly views AI-assisted sperm detection as representing an important advancement in fertility medicine, with the potential to become standard equipment in fertility centers worldwide within the next few years.

Source: BBC